July 21, 2009 -
Tim Horn -
... dosing, whereas Gilead s experimental once-daily compound elvitegravir requires a low-dose Norvir (ritonavir) booster. Second ... HIV that has become resistant to Isentress or elvitegravir. The study reviewed at IAS by Sherene Min ... with other integrase inhibitors specifically Isentress (raltegravir) and elvitegravir, neither of which were used as comparisons in ... In previous 10-day studies of Isentress and elvitegravir, average maximum viral load reductions were 1.7 ... enzyme conferring resistance to GSK-572, Isentress or elvitegravir were found. No severe side effects were ...
http://www.aidsmeds.com/articles/hiv_gsk1349572_integrase_1667_16953.shtml
July 21, 2009 -
Tim Horn -
... dosing, whereas Gilead s experimental once-daily compound elvitegravir requires a low-dose Norvir (ritonavir) booster. Second ... HIV that has become resistant to Isentress or elvitegravir. The study reviewed at IAS by Sherene Min ... with other integrase inhibitors specifically Isentress (raltegravir) and elvitegravir, neither of which were used as comparisons in ... In previous 10-day studies of Isentress and elvitegravir, average maximum viral load reductions were 1.7 ... enzyme conferring resistance to GSK-572, Isentress or elvitegravir were found. No severe side effects were ...
http://www.aidsmeds.com/articles/hiv_gsk1349572_integrase_2351_16953.shtml
February 17, 2009 -
David Evans -
... GS 9350, in tandem with its integrase inhibitor, elvitegravir (which currently requires Norvir boosting), and will package ...
http://www.aidsmeds.com/articles/hiv_drugs_development_2042_16129.shtml
February 9, 2009 -
Tim Horn -
... boost blood levels of its experimental integrase inhibitor elvitegravir. Currently, elvitegravir must be taken twice a day; GS 9350 ... four-in-one drug containing GS 9350-boosted elvitegravir plus emtricitabine (Emtriva) and tenofovir (Viread). It is ... levels using fixed-dose tablets containing GS 9350, elvitegravir, emtricitabine and tenofovir. One version of the tablet ... were compared with a regimen containing Norvir-boosted elvitegravir plus Truvada (emtricitabine/tenofovir). The combination tablet ...
http://www.aidsmeds.com/articles/gilead_sequoia_booster_1667_16072.shtml
February 9, 2009 -
Tim Horn -
... boost blood levels of its experimental integrase inhibitor elvitegravir. Currently, elvitegravir must be taken twice a day; GS 9350 ... four-in-one drug containing GS 9350-boosted elvitegravir plus emtricitabine (Emtriva) and tenofovir (Viread). It is ... levels using fixed-dose tablets containing GS 9350, elvitegravir, emtricitabine and tenofovir. One version of the tablet ... were compared with a regimen containing Norvir-boosted elvitegravir plus Truvada (emtricitabine/tenofovir). The combination tablet ...
http://www.aidsmeds.com/articles/gilead_sequoia_booster_2297_16072.shtml
July 23, 2008 -
July 23, 2008 Gilead s Elvitegravir Enters Phase III Studies A Phase III clinical ... Gilead Science s once-daily experimental integrase inhibitor elvitegravir is now open and enrolling patients, according to ... implies, integrase inhibitors work by blocking this process. Elvitegravir, also known as GS-9137 and JTK 303 ... treatment options. Gilead is hoping to show that elvitegravir, given once daily with a low dose of ... Puerto Rico. Participants will receive either once-daily elvitegravir or twice-daily raltegravir and, based on ...
http://www.aidsmeds.com/articles/hiv_aids_elvitegravir_1667_14962.shtml
October 23, 2007 -
David Evans -
... of Isentress—as well as Gilead Science’s elvitegravir, which is currently in Phase II studies—turned ...
http://www.aidsmeds.com/articles/HIV_Isentress_integrase_2042_13308.shtml
September 19, 2007 -
Tim Horn -
September 19, 2007 Elvitegravir Study Highlights Value of Strong Background Regimen by ... other promising experimental drugs, Gilead’s integrase inhibitor elvitegravir needs to be combined with other active drugs ... week data from a Phase II study of elvitegravir were reported earlier this year at the 14th ... patients to receive one of three doses of elvitegravir (20 mg, 50 mg or 125 mg), combined ... Fuzeon (enfuvirtide). After eight weeks, patients in the elvitegravir groups were permitted to add Norvir-boosted ...
http://www.aidsmeds.com/articles/HIV_elvitegravir_integrase_1667_13052.shtml
September 19, 2007 -
Tim Horn -
Elvitegravir Study Highlights Value of Strong Background Regimen September ... other promising experimental drugs, Gilead’s integrase inhibitor elvitegravir needs to be combined with other active drugs ... week data from a Phase II study of elvitegravir were reported earlier this year at the 14th ... patients to receive one of three doses of elvitegravir (20 mg, 50 mg or 125 mg), combined ... Fuzeon (enfuvirtide). After eight weeks, patients in the elvitegravir groups were permitted to add Norvir-boosted ...
http://www.aidsmeds.com/articles/HIV_elvitegravir_integrase_2076_13052.shtml
August 8, 2007 -
Tim Horn -
... is cross-resistance between Isentress and Gilead s elvitegravir, currently in Phase II studies HIV that develops ...
http://www.aidsmeds.com/articles/2042_12723.shtml
